Showing posts with label Companies. Show all posts
Showing posts with label Companies. Show all posts

Wednesday, 18 September 2013

Box joins crew of companies trying to disrupt Microsoft Office

You knew it had to happen.

A year ago, file storage and collaboration service Box hired Sam Schillace, the creator of cloud-based document creation tool Writely, which later became Google Docs, the cornerstone of Google Apps. At first, Apps was considered a joke, way behind on features and suitable only for individuals and small businesses. Eventually, it made enough inroads into enough enterprises that Microsoft targeted Apps in its sales process and created its own cloud-based competitors, Office Web Apps and Office 365. It's a classic tale of disruption.

Today, Box announced that it's starting down the same road as Google, adding document creation to its cloud-based file storage and collaboration service. The new Box Notes feature is just entering private beta, and it's Web-only at this phase -- a major drawback given Box's stated intention to become the collaboration tool of choice for the cloud-plus-mobile world -- but it's a clear statement of intention.

[ Also on CITEworld: Salesforce realizes nobody wants to store their files in Salesforce ]

Way behind Word -- on purpose
In terms of features, Box Notes will launch leagues behind Microsoft Word. It's really more of a note-taking app -- akin to OneNote -- than a full word processor, although it does have basic formatting features.

Rather, the most important aspects are real-time concurrent editing, annotations, and a strong social element -- for instance, small visual avatars tell you exactly who's working on which parts of a file at a given time.

Schillace said that Box is trying to think of document creation the way Apple thought about smartphones when it began designing the iPhone -- by thinking hard about what to leave out. "Everybody was trying to squeeze the desktop into a mobile device, like PalmOS or Danger... It was funky and weird, and didn't quite work right. Apple started making choices about what to put in and what to leave out, and it worked much better for that form factor."

Box joins crew of companies trying to disrupt Microsoft Office
Box Notes contains basic formatting tools (top), annotations (bottom), and a feature called Note Heads (left) that tells you who's working in a particular part of an app.

He believes document creation is now in the same phase as mobile phones were seven years ago. Traditional word processing was invented for a world when information workers wrote business letters and mailed them back and forth. That started to become a niche scenario with the advent of email and other forms of online communication. It's become completely ridiculous with the mobile web.

"It would be really miserable if you had to write up every email you wrote as a formal business letter," said Schillace. "Think about doing that with all your texts, it would be ridiculous. That artifact is actively getting in the way where documents are just carriers for the business intent, the social intent, the communications."

Others are thinking along the same lines, particularly Quip, a social-mobile word processing app that launched last month under the leadership of former Facebook CTO (and former Googler) Bret Taylor. Schillace admitted he was "a little annoyed" when he heard about Quip because Box had been working on Notes for many months by that time.

But Shillace believes there's room for multiple players, saying several times that document creation is "not a zero sum game."

As far as Google goes, he believes Box's enterprise focus will help it stand apart. "If I wanted to compete with Google Docs I'd do Google Docs again," he said. "We're deeper into the platform end and enterprise support than Google Docs. Enterprise is a bit of a messy game, and Google doesn't like things that don't scale that well, they like things to be more automated. There are lots of ways we can add value and be part of their ecosystem to solve real problems. We partner with them and want to be integrated with them."

So once Box Notes is done, will Box turn its attention to disrupting other parts of the Office suite? Schillace says no to Excel -- it's too specialized and well-entrenched as a platform for financial workers, although there are particular use cases (like using Excel as a simple ad hoc database) that might be interesting.

And although Schillace personally believes that "PowerPoint should die in a fire," Box has no plans to go after it any time soon.

Expect Box Notes to be a big focus at this year's BoxWorks conference, which kicks off later today in San Francisco. I'll be on hand to cover any more news from the show and talk to some Box customers.

Matt Rosoff is the editorial director of CITEworld. Read Matt's bio

This story was originally published at CITEworld.


View the original article here

Monday, 9 September 2013

WLAN growth slows after companies rush 802.11n upgrades

IDG News Service - Because many enterprises have already upgraded their networks to the 802.11n standard, sales growth in the enterprise wireless LAN sector was cut in half during the second quarter, according to Infonetics Research.

Global wireless LAN (WLAN) equipment revenue increased by 14 percent year-on-year in the second quarter, compared to a jump of almost 30 percent year-on-year during the same period last year, according to Matthias Machowinski, directing analyst at Infonetics. Still, equipment for WLANs remains the fastest growing network segment, he said.

The major event this quarter was initial shipments of enterprise class access points based on 802.11ac -- which is the latest standard for WLANs and promises increased speeds, network reliability and the ability to handle more users. But the impact of 802.11ac on overall sales will be minor this year because many enterprises have just upgraded to 802.11n, Machowinski said.

Wireless industry expert Roger Hockaday agreed:

"There is no burning desire to move to 802.11ac at the moment, apart for in some very specific high density environments, like a university lecture theater," he said.

But while many large enterprises are in a holding pattern, service providers are increasing their investments. For example, shipments of access points for outdoor use grew by 22 percent year-on-year during the second quarter, propelled by service provider deployments, according to Infonetics.

The growth also comes from public indoor areas such as shopping malls, according to Hockaday. He also thinks small and medium-size companies will show a growing interest in building WLANs.

"When you talk to medium sized companies, they don't see wireless as critical, because they haven't seen the need yet. But I think that will change, as more laptops come without an Ethernet port and the use of tablets grow," Hockaday said.

The perennial leaders in the WLAN market -- Cisco Systems and Aruba Wireless -- both turned in solid performances during the second quarter and grew their share of overall revenue, according to Infonetics.

Send news tips and comments to mikael_ricknas@idg.com

Reprinted with permission from IDG.net. Story copyright 2012 International Data Group. All rights reserved.

View the original article here

Monday, 12 August 2013

FDA Rejection Of Augment Graft Improves Future For Smaller Companies

The failure of Wright Medical Group’s (WMGI) Augment bone graft to get past the FDA was not wholly unexpected in light of its first-time defeat and an almost perfunctory attempt to plug the holes in the data for the resubmission. Nevertheless Wright’s investors appeared to be taken by surprise, sending the company’s shares down 8% on Friday.

Augment’s denial leaves Medtronic (MDT) and Integra LifeSciences (IART) dominating the market for these contentious products, EvaluateMedTech data show. But with Medtronic’s flagship orthobiologic graft Infuse beset by negative trial findings, its bone filler sales are set to stagnate. Indeed, consensus forecasts show that the companies with the fastest-growing orthobiologic sales are relative minnows in the sector (see table).

Deals

Wright itself is stuck in neutral following the FDA’s non-approvable letter for Augment’s use in hindfoot and ankle fusion. The company had bet big on Augment, selling its hip and knee business to MicroPort Scientific less than two months ago as part of a biologics-focused strategy which looked risky at the time (MicroPort’s Wright turn could lead to parallel ortho market, June 21, 2013).

It is Wright’s other recent deal that the rejection affects most profoundly. Wright bought fellow Tennessee firm BioMimetic in November for $190m upfront, principally to obtain Augment. The deal was structured so that each BioMimetic share entitled its holder to up to $6.50 on Augment being approved in the US and hitting sales milestones (BioMimetic buy could augment Wright’s orthopaedic offering, November 20, 2012).

While the FDA has left the door open for Wright to conduct further trials and reapply, BioMimetic shareholders will be waiting a good while before they see that $6.50.

Up for grabs

With its principal biologic bone filler going nowhere in the U.S. – though it is still undergoing European review – the forecast worldwide sales for Wright’s orthobiologics segment will surely be revised downwards.

Wright’s predicted 2018 sales of $78m are therefore up for grabs. And the grabbiest company appears to be San Diego group NuVasive (NUVA), whose orthobiologic bone filler sales are predicted to grow at a rate of 73%, EvaluateMedTech’s data shows. Its AttraX biologic is awaiting FDA 510(k) clearance; analysts at Barclays Capital expect approval in the first quarter of next year.

The biggest player by far in orthobiologics is Medtronic. Consensus shows that its sales are barely growing, though individual analysts’ predictions for its main biologic, spinal fusion product Infuse, vary quite widely following some negative trial results (Infuse trials backfire on Medtronic with negative findings, June 18, 2013).

Biologics for bone fusion procedures are tricky to get approved, have never wholly proven their safety and are not setting the market alight in terms of sales. Now Augment is delayed or perhaps even killed off entirely, companies might be wise to give this area a miss, even though a competitor has taken a step back.

Worldwide sales forecasts ($m) for orthobiologic bone filler segments

All data sourced to EvaluateMedTech


View the original article here

Sunday, 11 August 2013

China Biotech In Review: Fundings For China-Affiliated Drug Companies

Deals and Financings

Shenogen Pharma of Beijing raised $20 million in a series C funding, which the company will use to support a Phase II trial of its lead drug candidate, icaritin, a small molecule drug that targets the estrogen receptor alpha 36. The trial will enroll patients with hepatocellular cancer. The drug is derived from barrenwort, a TCM. The funding was led by Legend Capital and Qiming Weichuang Venture Capital. Investors also received warrants to buy an additional $10 million in shares.

Apexigen, a California antibody company with strong connections to several China pharmas, brought in $20 million in a Series A1 financing. Apexigen was originally the drug development arm of Epitomics, a company built around a rabbit-based platform for developing monoclonal antibodies. Two China companies - Simcere (NYSE: SCR) and 3SBio (NSDQ: SSRX) - have filed with the CFDA to begin clinical trials of Apexigen-discovered drugs.

Zhongyuan Union Stem Cell Bioengineering (SHA: 600645) formed a stem cell JV with Cell Therapy Ltd. of Wales. The JV will focus on developing stem cell therapies for major diseases such as heart disease and diabetes, presumably based on CTL's technology. It plans to build two operational hubs near Shanghai and Beijing, with smaller offices in other China cities. The two firms will share the JV's China revenues equally, while Cell Therapy will have first option on Zhongyuan Union's products outside China.

Sinopharm Group will build a China Biotechnology Research Institute in Wuhan East Lake High-tech Zone, gathering together its existing biotech R&D resources into one location. The facility will be part of a Sinopharm subsidiary, the China Institute of Pharmaceutical Industry. Sinopharm says the Institute will be the largest biotech R&D operation in China, comprising two to three separate buildings. Construction will take three years.

ScinoPharm (TAI: 1789), a Taiwan CRO with expertise in process development and generic API production, formed a strategic alliance with Sundia MediTech Company, the Shanghai CRO. The two companies will collaborate to provide Contract Research and Manufacturing Services (CRAMS) in China. ScinoPharma will participate through its China subsidiary, ScinoPharm Changshu.

Mitsubishi Tanabe Pharma will spend $19.5 million to build a new China production facility in Tianjin. The plant will be owned by Tianjin Tanabe Seiyaku, a joint venture in which Mitsubishi holds a 75% stake. Its local partner, Tianjin Lisheng Pharmaceutical Co., owns the remaining 25%. The new facility will be built on the JV's existing site in the Tianjin Economic Development Area.

Komtur Pharmaceuticals, a German clinical trial sourcing company, set up a China JV with HengHeKangJian Pharmaceutical. The JV will build a state-of-the-art distribution center that is compliant with the latest China and international standards. It will offer distribution of clinical trial supplies and sourcing of reference drugs. The JV will also provide commercial distribution of finished pharmaceuticals and medical devices, and will eventually move into pharmaceutical labeling and re-packaging.

Allium Medical ((TASE: ALMD)) of Israel signed up Beijing King Health Investment to distribute the company's urinary tract stents in China. King Health agreed to buy at least $16 million of Allium's stents during the eight-year run of the contract. The two companies expect to launch the urinary stents in 2016, assuming CFDA approval.

Trials and Approvals

A JV consisting of Zoetis (NYSE: ZTS), the recently spun-off animal health subsidiary of Pfizer (NYSE: PFE), and Jilin Guoyuan Animal Health Co. has received marketing approval in China for a new swine vaccine (see story). Rui Lan An™ targets highly pathogenic porcine reproductive and respiratory syndrome (HP PRRS). The JV, which was announced in 2011, will launch the vaccine immediately. Zoetis/Pfizer and Jilin Guoyuan formed the JV to meet the needs of China's livestock producers, particularly the pork industry.

Company News

According to press reports, Sanofi (NYSE: SNY) paid China doctors kickbacks to prescribe its blood pressure drugs (see story). An anonymous whistleblower alleged that the company's representatives paid 1.7 million RMB ($280,000) to over 500 doctors in 79 hospitals - about $500 each. The illegal payments, which were made in November 2007, were billed as research fees or grants, said the whistleblower.

Disclosure: none.


View the original article here